1. Home
  2. LLY

LLY

Eli Lilly and Company

Logo Eli Lilly and Company

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Founded: 1876 Country:
United States
United States
Employees: N/A City: INDIANAPOLIS
Market Cap: 690.6B IPO Year: N/A
Target Price: $714.14 AVG Volume (30 days): 3.1M
Analyst Decision: Strong Buy Number of Analysts: 23
Dividend Yield: 0.71% Dividend Payout Frequency: Quarterly
EPS: 5.80 EPS Growth: -15.94
52 Week Low/High: $367.35 - $800.78 Next Earning Date: 04-30-2024
Revenue: $34,124,100,000 Revenue Growth: 19.56%
Revenue Growth (this year): 22.48% Revenue Growth (next year): 24.96%

Share on Social Networks:

Stock Insider Trading Activity of Eli Lilly and Company (LLY)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
LILLY ENDOWMENT INC LLY 10% Owner Feb 15 '24 Sell $760.19 41,053 $31,208,121.12 99,077,757 SEC Form 4
LILLY ENDOWMENT INC LLY 10% Owner Feb 15 '24 Sell $761.56 7,863 $5,988,130.55 99,069,894 SEC Form 4
LILLY ENDOWMENT INC LLY 10% Owner Feb 15 '24 Sell $762.26 1,400 $1,067,165.40 99,068,494 SEC Form 4
LILLY ENDOWMENT INC LLY 10% Owner Feb 8 '24 Sell $740.06 8,743 $6,470,335.84 99,325,067 SEC Form 4
LILLY ENDOWMENT INC LLY 10% Owner Jan 29 '24 Sell $645.07 54,032 $34,854,422.24 99,488,598 SEC Form 4
LILLY ENDOWMENT INC LLY 10% Owner Jan 16 '24 Sell $645.55 1,080 $697,188.60 99,542,730 SEC Form 4
LILLY ENDOWMENT INC LLY 10% Owner Jan 16 '24 Sell $646.17 100 $64,617.00 99,542,630 SEC Form 4
Zakrowski Donald A LLY SVP, Finance, & CAO Nov 6 '23 Sell $571.10 670 $382,637.00 4,708 SEC Form 4

Similar to LLY Stocks: